Previous studies regarding trastuzumab action and resistance in breast cancer have been focused on its role in the Akt pathway, in the context of HRG-induced HER2–HER3 heterodimers [8,60,67,68,69,70,71,72,73,74,75,76,77]. Here, ERBB2 is linked to breast carcinoma.